Progyny, Inc. (PGNY) Research

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Market snapshot

Symbol
PGNY
Price
$26.08
Day change
-0.87%
Market cap
$2.0B
P/E ratio
31.18x
52-week range
16.1-28.75
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Next earnings
in 2 months
Analyst price target
$30.33

Peer companies

  • Alvotech (ALVO)
  • GoodRx Holdings, Inc. (GDRX)
  • Omnicell, Inc. (OMCL)
  • Omada Health (OMDA)
  • Phreesia, Inc. (PHR)
  • Schrödinger, Inc. (SDGR)
  • Select Medical Holdings Corporation (SEM)
  • Teladoc Health, Inc. (TDOC)

Recent insider activity

  • Livingston Mark S. — F-InKind (1082 shares) on 2026-06-03
  • Livingston Mark S. — F-InKind (339 shares) on 2026-06-04
  • Livingston Mark S. — S-Sale (1918 shares) on 2026-06-04
  • Livingston Mark S. — S-Sale (599 shares) on 2026-06-04
  • Swartz Allison — F-InKind (676 shares) on 2026-06-03

Open Progyny, Inc. (PGNY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.